Posted 1/15/2023 6:59 PM (GMT 0)
Checking in after my first three (of six) chemo (Docetaxel + Carboplatin) treatments, also on Lupron and Darolumatide (Nubeqa).
Thanks to all the great advice on this site, I've had minimal side effects except for the "chemo crash" which has been increasing in severity. I’ve been traveling from Massachusetts to Minneapolis for treatment, but last week went to Mayo/Rochester for a new PSMA Pet scan (Gallium 68) and to meet with my doctor. I’ve included the narrative/results below.
In short, my new scans show some tumor reduction, and the Standardized Uptake Values (SUV) also seem to be decreasing from levels on my earlier scan (9/26/22). Nothing dramatic in terms of improvement but, notably, no increases in size and no new cancer is evident. My PSA, for whatever that’s worth, has been undetectable since November, when I started back on Lupron. (PSA has always been low and never a reliable indicator of my PCa.)
Doc says this is the progress he would expect after three treatments. Also, he says the Max SUV scores show the cancer still lighting up; he believes that dead cancer cells still emit this energy for some weeks after they die, so he expects to see that.
I have three more treatments, ending February 28, and then I go back to Mayo March 29-30 for additional PSMA Pet scan, MRI, blood tests and my quarterly Lupron shot. By that time, my doctor believes we should see significant reduction of the disease…and we will chart next steps, likely radio-ligand therapy (Lutetium-177 and/or Actinium-225).
While we will try to get treatment approved in US, doc says I might have to consider travel to a foreign country, such as Turkey. As I understand it, the FDA wants to see evidence that chemo and/or 2nd gen ADT (Nubeqa) have both failed, and the cancer is starting to return, before approving Lutetium-177. My doctor believes it’s important to move quickly with the therapy and keep killing cancer cells, and not to wait for them to go into remission then regroup…my gut (what else do I have to go on??) tells me to follow his advice. Would be interested in hearing thoughts on this...
Best wishes to fellow prostate cancer warriors as we head into 2023. Here's hoping for good treatments and successful outcomes, and thank you for providing such important support through this challenging journey!
RESULTS FROM MAYO SCAN:
Patient DOB: 09-Jul-1956 _____________________________________________________________________________
IMPRESSION:
Interval mild reduction in size of some of the previously seen widespread metabolically
active nodal disease, although significant PSMA avidity still remains both in the previously seen nodes as well as multifocal osseous metastasis.
miPSMA Expression Score: 3
EXAM: PET CT SKULL TO THIGH PSMA
RADIOPHARMACEUTICAL/MEDS:
Route: intravenous
gallium Ga 68 gozetotide injection (Ga-68 Illuccix/Locametz),5.49 millicurie
TECHNIQUE: Ga-68 PSMA PET/CT scan was performed from the orbits through the proximal thighs with low dose, non-contrast, free-breathing CT images for attenuation correction and anatomic
localization (AC/AL), with imaging beginning at approximately 60 minutes after radiotracer
injection.
COMPARISON: 09/26/2022
INDICATION: Prostate carcinoma restaging. Subsequent treatment strategy. PSA: <0.10
FINDINGS: Compared to prior examination, and allowing for differences in technique, there is mild interval treatment response with primarily reduction in size of the PSMA avid previously seen retroperitoneal lymphadenopathy. For example, one of the previously seen and a larger left
periaortic lymph nodes measured 1.2 x 1.2 cm and now measures approximately 9 x 9 mm, though still demonstrating intense PSMA localization (SUV max 10.1). Similar mild improvement is also noted within the other nodal basins previously involved including the bilateral iliac, subcarinal,
bilateral hilar, pretracheal, prevascular, and bilateral supraclavicular nodes. Persistent
radiotracer uptake is also noted within the multiple scattered osseous metastases, most prominently involving C2 vertebral body (SUV max 12.2), T10, L1, L2, and L5 vertebral bodies as well as multiple ribs and involving the pelvis. The the largest osseous metastasis continues to be in the L3
vertebral body filling almost the entire vertebral body (SUV max 25.7).